RESULTS

SINGLE SERUM NUCLEOSOME BIOMARKER IN PROSTATE CANCER

VolitionRx has performed a retrospective study on blood samples collected from 537 patients, including 266 men with prostate cancer and 271 age-matched healthy controls, and analysed the samples with a single serum NuQ® adduct biomarker ELISA assay.

RESULTS PANEL NUCLEOSOME BIOMARKERS IN NSCLC, CRC & PC

NSCLC: A study of 73 patients conducted with Liege University Hospital, Belgium, showed that a panel of 4 epigenetic nucleosome assays combined with smoking history detected 93% of NSCLC cases, with 91% specificity and differentiated NSCLC and COPD.

COLORECTAL CANCER: A collaborative study of 121 patients referred for colonoscopy at the CHU Dinant Godinne - UCL Namur, Belgium found that a panel test of five epigenetic nucleosome biomarker assays detected 87% of colorectal cancer cases and 67% of dysplastic polyps at 90% specificity.

PANCREATIC CANCER: A 59 subject collaborative study with Lund University, Sweden, found that a panel of 4 epigenetic nucleosome ELISA assays and CA19-9 detected 92% of stage II pancreatic cancer cases, with 100% specificity among healthy subjects and 2 false positives among patients with benign pancreatic disease.

CONCLUSION: Epigenetic profiling of circulating nucleosomes using simple ELISA methods offers a biomarker opportunity for the early detection of a variety of cancers.